January 2, 2013 – A recent financial report from drug maker Bayer says that approximately 13,000 lawsuits have been filed by patients claiming injury from the birth control drugs Yaz and Yasmin. Although the company is settling many cases, the Yaz Center warns time may be limited for those who haven’t filed a claim.
Last fall, the American College of Obstetricians and Gynecologists became the latest group to warn consumers that birth control pills which use the hormone drospirenone, like Yaz and Yasmin, can lead to higher risks of blood clots.
In 2011, both the British Medical Journal and FDA published research which also related the hormone in Yaz to blood clots, saying drospirenone could increase occurrences by as much as 74%.
With estimates that Bayer has only settled around 3500 Yaz lawsuits so far, many assume the payouts will go on for years. However, the Yaz Resource Center cautions that Yaz claims and settlements could be concluded by the middle of 2013.
First, Bayer’s latest report indicated it was setting aside more funds to settle Yaz claims, but indicated the company was only resolving claims over blood clot injuries such as stroke, pulmonary embolism or deep vein thrombosis. These could be less than half of all the claims filed.
Second, last July, Stephen Saltzberg, the court officer appointed to oversee settlement negotiations for the federal Yaz court, estimated the settlements could be concluded within a year, which would put a deadline at around summer of 2013.
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Yaz Resource Center or speak with a lawyer about their legal options as soon as possible.
The Yaz Resource Center cautions that victims should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.
Contact us today for more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer.